Amplifying the concept of psoriatic arthritis: The role of autoimmunity in systemic psoriatic disease

Chimenti, Maria Sole; Caso, Francesco; Alivernini, Stefano; Martino, Erica De; Costa, Luisa; Tolusso, Barbara; Triggianese, Paola; Conigliaro, Paola; Gremese, Elisa; Scarpa, Raffaele; Perricone, Roberto

doi:10.1016/j.autrev.2018.11.007

Cited by 51 publications

(30 citation statements)

References 121 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients with more severe disease may be at higher risk of developing mental health comorbidities, while some mental disorders have been shown to exacerbate the perception of pain [6 ]. Systemic inflammation may influence neurocognitive functions [53,54]. Only two studies compared disease activity between PsA patients with and without mental health comorbidities.…”

Section: Mental Health Comorbidities and Disease Activitymentioning

confidence: 99%

Systematic review of mental health comorbidities in psoriatic arthritis

et al. 2019

View full text Add to dashboard Cite

Objective In this systematic review and meta-analysis of psoriatic arthritis (PsA) studies, we pooled data from existing literature to (1) estimate the prevalence of mental health disorders in PsA patients and (2) compare disease activity in PsA patients with and without these comorbidities. Method We searched PubMED, Web of Science, Scopus, PsycINFO and the Cochrane Library using a predefined protocol in accordance with Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. Where possible, meta-analysis was performed using random effects model. Prevalence estimates were pooled according to the severity of mental health disorders. Results A total of 24 studies, amounting to 31,227 PsA patients, were included for review. Anxiety and depression were the only consistently reported mental health disorders, defined using a range of screening criteria/thresholds. Anxiety prevalence ranged from 4 to 61% with a pooled estimate of 33% (95%CI 17 to 53%) having at least mild anxiety and 21% (95%CI 14 to 29%) at least moderate. Depression prevalence ranged from 5 to 51%, with 20% (95%CI 8 to 35%) having at least mild and 14% (95%CI 8 to 21%) at least moderate. Only two studies compared disease activity according to the presence of mental health comorbidities; both reported higher disease activity and pain among those with comorbid anxiety and depression. Conclusions Anxiety and depression are highly prevalent among PsA patients. Studies of other mental health disorders were scarce. More studies are needed on the impact of these comorbidities on disease activity and long-term outcomes.

show abstract

Section: Mental Health Comorbidities and Disease Activitymentioning

confidence: 99%

Systematic review of mental health comorbidities in psoriatic arthritis

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The disease activity in patients with PsA was assessed by an experienced rheumatologist at the time of recruitment using tender (68 joints) and swollen joint (66 joints) count, enthesitis (Yes/No), dactylitis (Yes/No), relevant patient reported outcomes (PROs) such as Visual Analogue Scale of pain (VASp) and global health (VASgh), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Health Assessment Questionnaire modified for SpA (HAQ-SpA) [22]. The Disease Activity in Psoriatic Arthritis (DAPSA) score [23] and the Disease Activity Score (DAS) were used as composites clinimetric indexes [24].…”

Section: Rheumatologic Assessmentmentioning

confidence: 99%

A Multimodal Eye Assessment in Psoriatic Arthritis Patients sine-Psoriasis: Evidence for a Potential Association with Systemic Inflammation

Chimenti

Triggianese

Salandri

et al. 2020

JCM

Self Cite

View full text Add to dashboard Cite

Background: Ocular involvement in Psoriatic Arthritis (PsA) patients is mainly associated with uveitis but there remains a paucity of data on dry eye and retinal abnormalities. We aimed to analyze dry eye and subclinical retinal abnormalities in a cohort of PsA patients sine-psoriasis (PsO). Methods: PsA patients sine-PsO were enrolled. Best-corrected-visual-acuity, ocular-surface-disease-index (OSDI), Schirmer test, tear film breakup-time, standard-automated-perimetry (SAP, mean deviation—MD, pattern standard deviation—PSD), fundus-perimetry (FP), and spectral-domain-optical-coherence-tomography (SD-OCT) were performed. Results: A total of 80 eyes from 40 PsA patients with moderate-severe disease activity, and 70 eyes from 35 healthy control (HC) were evaluated. Higher dry eye prevalence occurred in PsA than HC (p < 0.0001). ESR was positively related with OSDI (p < 0.001) and negatively related with Schirmer (p = 0.007). In PsA, SAP registered higher MD (p < 0.0001) and higher PSD (p = 0.005) in comparison with HC. PSD resulted positively correlated with ESR (p = 0.04) and CRP (p = 0.01), while MD showed a negative correlation with CRP (p = 0.01). Both FP mean differential sensitivity and mean defect were lower in PsA then HC (p < 0.0001). In PsA, FP differential sensitivity was directly related with cumulative steroids (p = 0.02). Conclusions: In PsA patients sine-PsO, dry eye and subclinical abnormalities in visual functions occurred being potentially related to systemic inflammation.

show abstract

“…Псориатический артрит (ПсА) -ИВРЗ, которое, с одной стороны, рассматривается как наиболее частая коморбидная патология при псориазе в рамках «системной псориатической болезни» [7], а с другой -классифицируется как клиническая форма спондилоартритов (СпА) [8], находится на стыке фундаментальных проблем ревматологии и дерматологии. ПсА -гетерогенное заболевание в отношении как патогенеза, характеризующегося комплексным взаимодействием факторов внешней среды, генетической предрасположенности, аутоим-мунных и аутовоспалительных механизмов [9][10][11][12], так и спектра клинических проявлений, вариантов течения и исходов, и фактически он представляет собой клинико-иммунологический синдром. В настоящее время в лечении ПсА достигнут существенный прогресс, связанный с применением генно-инженерных биологических препаратов (ГИБП) [13][14][15][16][17][18], блокирующих патогенетически значимые цитокины (табл.…”

Section: псориатический артритunclassified

Efficacy and Safety of Tofacitinib for Immunemediated Inflammatory Rheumatic Diseases (Part Ii)

Nasonov

Авдеева²,

Лила

2020

Naučno-praktičeskaâ revmatologiâ

View full text Add to dashboard Cite

Разработка «таргетных» пероральных противовоспалительных лекарственных препаратов-ингибиторов Янус-киназ (Janus kinase, JAK) [1, 2], первым представителем которых является тофацитиниб (ТОФА), рассматривается как крупное достижение био-П р о г р е с с в р е в м а т о л о г и и в X X I в е к е Насонов Е.Л.научный руководитель ФГБНУ «НИИР им. В.А. Насоновой», академик РАН, профессор, докт. мед. наук 1 ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»,

show abstract

Amplifying the concept of psoriatic arthritis: The role of autoimmunity in systemic psoriatic disease

Cited by 51 publications

References 121 publications

Systematic review of mental health comorbidities in psoriatic arthritis

Systematic review of mental health comorbidities in psoriatic arthritis

A Multimodal Eye Assessment in Psoriatic Arthritis Patients sine-Psoriasis: Evidence for a Potential Association with Systemic Inflammation

Efficacy and Safety of Tofacitinib for Immunemediated Inflammatory Rheumatic Diseases (Part Ii)

Contact Info

Product

Resources

About